We are live on ! Find out more
SUPN icon

Supernus Pharmaceuticals
SUPN

244 hedge funds and large institutions have $1.86B invested in Supernus Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 39 funds opening new positions, 91 increasing their positions, 76 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

105% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 19

30% more capital invested

Capital invested by funds: $1.42B → $1.86B (+$433M)

20% more repeat investments, than reductions

Existing positions increased: 91 | Existing positions reduced: 76

8% more funds holding

Funds holding: 225 → 244 (+19)

1.55% more ownership

Funds ownership: 102.49% → 104.05% (+1.6%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

23% less call options, than puts

Call options by funds: $2.16M | Put options by funds: $2.79M

Holders
244
Holders Change
+19
Holders Change %
+8.44%
% of All Funds
4.2%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
39
Increased
91
Reduced
76
Closed
19
Calls
$2.16M
Puts
$2.79M
Net Calls
-$636K
Net Calls Change
+$182K

Top Buyers

1
BlackRock
BlackRock
New York
+$13.7M
2
IBT
International Biotechnology Trust
United Kingdom
+$9.4M
3
EA
Emerald Advisers
Pennsylvania
+$7.93M
4
WP
Woodline Partners
California
+$7.33M
5
Citadel Advisors
Citadel Advisors
Florida
+$7.05M

Top Sellers

1
MFIMFI
Mesirow Financial Investment Management - Fixed Income
Illinois
-$11.5M
2
SCM
Soleus Capital Management
Connecticut
-$7.46M
3
Millennium Management
Millennium Management
New York
-$7.06M
4
RHJA
Rice Hall James & Associates
California
-$5.03M
5
GKIM
GW&K Investment Management
Massachusetts
-$4.63M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$312M +$13.7M +420,429 +5%
Vanguard Group
2
Vanguard Group
Pennsylvania
$192M +$1.95M +59,794 +1%
AC
3
Armistice Capital
New York
$155M -$3.87M -118,996 -3%
Macquarie Group
4
Macquarie Group
Australia
$80.2M +$1.07M +32,816 +1%
Dimensional Fund Advisors
5
Dimensional Fund Advisors
Texas
$76.9M +$1.02M +31,355 +1%
State Street
6
State Street
Massachusetts
$65.1M -$1.79M -54,886 -3%
GKIM
7
GW&K Investment Management
Massachusetts
$59.8M -$4.63M -142,360 -7%
SIMG
8
Stephens Investment Management Group
Texas
$54.4M -$214K -6,576 -0.4%
Loomis, Sayles & Company
9
Loomis, Sayles & Company
Massachusetts
$54.2M -$314K -9,659 -0.6%
Renaissance Technologies
10
Renaissance Technologies
New York
$43.3M -$3.8M -116,800 -8%
ACB
11
Aristotle Capital Boston
Massachusetts
$39.2M -$3.59M -110,187 -9%
ACM
12
Ashford Capital Management
Delaware
$37M -$1.14M -34,984 -3%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$32.1M +$318K +9,769 +1%
WP
14
Woodline Partners
California
$26.9M +$7.33M +225,188 +40%
Ameriprise
15
Ameriprise
Minnesota
$26.9M -$1.03M -31,503 -4%
Victory Capital Management
16
Victory Capital Management
Texas
$26.3M -$236K -7,251 -0.9%
FCM
17
Frontier Capital Management
Massachusetts
$23.8M +$2.81M +86,433 +14%
Northern Trust
18
Northern Trust
Illinois
$23.4M -$24.3K -748 -0.1%
RHJA
19
Rice Hall James & Associates
California
$23M -$5.03M -154,641 -19%
Invesco
20
Invesco
Georgia
$21.5M -$1.56M -47,887 -7%
Bank of New York Mellon
21
Bank of New York Mellon
New York
$17.6M +$316K +9,723 +2%
Morgan Stanley
22
Morgan Stanley
New York
$17.5M +$1.36M +41,705 +9%
T. Rowe Price Associates
23
T. Rowe Price Associates
Maryland
$17.2M -$28.8K -885 -0.2%
CAM
24
Congress Asset Management
Massachusetts
$17.2M +$843K +25,921 +5%
EIP
25
Epoch Investment Partners
New York
$16.6M +$495K +15,199 +3%
1
2 3 4 5

SUPN Hedge Fund Activity: Q3 2022 in Review

244 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q3 2022, worth a combined $1.86B — up 30% from $1.42B a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new SUPN positions and 19 closed out — a net gain of 20 holders — while 91 added to existing stakes and 76 trimmed.

The largest buyer was BlackRock, adding an estimated $13.7M. The largest seller was Mesirow Financial Investment Management - Fixed Income, exiting entirely with an estimated $11.5M sold.

  • 244 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q3 2022, up from 225 in Q2 2022.
  • Funds reported $1.86B of Supernus Pharmaceuticals stock for Q3 2022, up 30% quarter-over-quarter.
  • 39 funds opened new Supernus Pharmaceuticals positions in Q3 2022 and 19 closed out, a net change of +20 holders.
  • The largest Supernus Pharmaceuticals buyer in Q3 2022 was BlackRock, an estimated $13.7M added.
  • The largest Supernus Pharmaceuticals seller in Q3 2022 was Mesirow Financial Investment Management - Fixed Income, an estimated $11.5M sold.

Based on aggregated 13F filings for Q3 2022.